Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Trastuzumab Deruxtecan

NCT07537673 | Recruiting Phase 2

• 1 other identifier: 20251807
• Study Type: interventional
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to learn if auricular point stimulation plus dexamethasone works to effectively prevent or suppress nausea and vomiting caused by trastuzumab deruxtecan in breast cancer palliative therapy. It will also learn about the safety and influence on gastrointestinal function of auricular point stimulation plus dexamethasone. The main questions it aims to answer are: Can auricular point stimulation plus dexamethasone effectively prevent or suppress nausea and vomiting induced by trastuzumab deruxtecan? Can auricular point stimulation plus dexamethasone effectively reduce the incidence of appetite loss, weakened or disordered gastrointestinal function, and other uncomfortable conditions caused by excessive use of antiemetic drugs? Participants will: Receive auricular acupressure with bean seeds on specific points of one ear, plus intravenous injection of dexamethasone as a preventive antiemetic treatment within half an hour before trastuzumab deruxtecan treatment. Starting from the day of trastuzumab deruxtecan treatment (Day 1) to the following five days (Day 1-Day 5), provide regular stimulation at the acupressure points daily by themselves according to the protocol provided in this trial. Record their nausea and vomiting status, appetite, and gastrointestinal function-related symptomatic indicators from Day 1 to Day 5. Oral antiemetics are also prepared. If nausea and vomiting are significant or the patient feels the need, they may be temporarily administered as an adjunct.

Conditions

Nausea and Vomiting Caused by Trastuzumab Deruxtecan

Outcome Measures

Primary Outcomes (1)

• Proportion of patients experiencing nausea as assessed by NIC-CTC AE4.0

  Participants will be asked to fill out a questionnaire to record whether nausea occurs. If nausea occurs, its grade according to the NIC-CTC AE4.0 should be recorded.

  from the day of trastuzumab deruxtecan treatment (Day 1) until the end of Day 5

Secondary Outcomes (2)

• Proportion of patients experiencing vomiting as assessed by NIC-CTC AE4.0

  from the day of trastuzumab deruxtecan treatment (Day 1) until the end of Day 5

• Proportion of patients requiring additional antiemetics

  from the day of trastuzumab deruxtecan treatment (Day 1) until the end of Day 5

Other Outcomes (1)

• Proportion of patients experiencing chemotherapy-related adverse events as assessed by CTCAE v4.0

  from the day of trastuzumab deruxtecan treatment (Day 1) until the end of Day 5

Study Arms (1)

Auricular point stimulation plus dexamethasone group

EXPERIMENTAL

For breast cancer patients who will receive trastuzumab deruxtecan for breast cancer palliative therapy, preventive antiemetic treatment consisting of unilateral auricular point stimulation at specific acupoints and dexamethasone will be administered within 30 minutes before chemotherapy. Auricular acupoint stimulation is performed by adhering Vaccaria seeds to specific points with adhesive tape and applying moderate pressure until a certain level of soreness is elicited. Vaccaria seeds are kept on the ear from the day of trastuzumab deruxtecan treatment (Day 1) until the end of Day 5.

Other: Auricular point stimulation plus dexamethasone

Interventions

Auricular point stimulation plus dexamethasone OTHER

On the day of trastuzumab deruxtecan treatment (d1): Within half an hour before chemotherapy, administer auricular acupressure on one ear (stimulating the stomach, cardia, and brainstem acupoints for 5 minutes each) along with an intravenous push of 5 mg dexamethasone. From the day of chemotherapy (d1) to the following five days (d1-d5): Stimulate each acupoint once in the morning, noon, and evening, for 5 minutes each time. If nausea or vomiting occurs, immediately apply additional stimulation for 5 minutes as a temporary measure. Oral antiemetics should be prepared and may be used temporarily if nausea and vomiting are significant and the patient feels the need.

Auricular point stimulation plus dexamethasone group

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years and ≤ 85 years;
• Breast cancer patients scheduled to undergo palliative treatment with trastuzumab deruxtecan;
• ECOG performance status score of 0-2;
• Normal hematological function (platelet count \> 80×10⁹/L; white blood cell count \> 3×10⁹/L; neutrophil count \> 1.5×10⁹/L);
• Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), and transaminase ≤ 5 times the ULN;
• No ascites, no gastrointestinal obstruction, normal coagulation function, and serum albumin ≥ 30g/L;
• Child-Pugh classification of liver function is Grade A;
• Serum creatinine \< ULN, or calculated creatinine clearance rate \> 50ml/min.

You may not qualify if:

• Local inflammation or infection of the auricle;
• Bleeding tendency or coagulation disorders;
• Severe ascites;
• Gastrointestinal obstruction;
• Hypertensive crisis or hypertensive encephalopathy;
• Severe uncontrolled systemic complications such as infection or diabetes mellitus;
• Clinically severe cardiovascular diseases, including cerebrovascular accident (within 6 months before enrollment), myocardial infarction (within 6 months before enrollment), hypertension that is not well-controlled despite appropriate medication, unstable angina pectoris, congestive heart failure (NYHA Class 2-4), and cardiac arrhythmias requiring drug treatment;
• A history of or physical examination findings indicating central nervous system diseases (e.g., primary brain tumor, epilepsy uncontrolled by standard treatment, any history of brain metastasis or stroke);
• Hypersensitivity to any drugs used in the study;
• Pregnant or lactating women;
• Presence of any other diseases, functional impairment caused by metastatic lesions, or suspicious disorders identified during physical examination, which suggest contraindications to the study drugs or place the patient at high risk of treatment-related complications;
• Inability or unwillingness to comply with the study protocol.

Sponsors & Collaborators

• Second Affiliated Hospital, School of Medicine, Zhejiang University: lead

Study Sites (1)

Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, China

RECRUITING

Related Publications (1)

• [1] STANKOWICZ M, MAURO L, HARNDEN K, et al. Management of Chemotherapy-Induced Nausea and Vomiting with Trastuzumab Deruxtecan: A Case Series. Breast care (Basel, Switzerland), 2021, 16(4): 408-11. [2] MODI S, JACOT W, YAMASHITA T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. The New England journal of medicine, 2022, 387(1): 9-20. [3] KIMURA S, HOSOYA K, OGATA K, et al. Severity of constipation related to palonosetron during first-line chemotherapy: a retrospective observational study. Support Care Cancer, 2021, 29: 4723-32.

  BACKGROUND

MeSH Terms

Conditions

Nausea

Interventions

Dexamethasone

Condition Hierarchy (Ancestors)

Signs and Symptoms, Digestive; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Pregnadienetriols; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Steroids, Fluorinated

Central Study Contacts

Juan Wang

CONTACT

8617816190946; wangjuan.happy@hotmail.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 14, 2025
• First Posted: April 17, 2026
• Study Start: November 25, 2025
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): November 1, 2026
• Last Updated: April 17, 2026

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)